- Home
- STTK
STTK
Shattuck Labs Inc.
as 09-16-2025 4:00pm EST
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 83.8M | IPO Year: | 2020 |
| Target Price: | $2.67 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $3.95 | Next Earning Date: | 11-13-2025 |
| Revenue: | $2,997,000 | Revenue Growth: | -27.33% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Shattuck Labs Inc. (STTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | STTK | Director | Aug 25 '25 | Buy | $0.87 | 6,306,127 | $5,471,826.40 | 5,255,106 | |
| Ashiya Mona | STTK | Director | Aug 25 '25 | Buy | $0.87 | 6,306,127 | $5,471,826.40 | 5,255,106 |
Latest Shattuck Labs Inc. News
STTK Breaking Stock News: Dive into STTK Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
8 days ago
Update: Wedbush Initiates Shattuck Labs at Outperform With $4 Price Target
Simply Wall St.
3 months ago
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
Simply Wall St.
4 months ago
Shattuck Labs First Quarter 2025 Earnings: US$0.27 loss per share (vs US$0.37 loss in 1Q 2024)
GlobeNewswire
5 months ago
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
Simply Wall St.
5 months ago
3 Promising Penny Stocks With Market Caps Under $300M
GlobeNewswire
5 months ago
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
6 months ago
Shattuck Labs Full Year 2024 Earnings: Misses Expectations
Compare STTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.